Please assess the completion status of the following clinical trial:

Trial Title: Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed malignancy~  * Metastatic or unresectable disease~ * Standard curative or palliative measures do not exist, are no longer effective, have been completed, or have been refused~* CEA-positive tumor (either by immunohistochemistry or as demonstrated by elevated CEA \> 50 μg/L)~* No primary brain tumor or brain metastases~PATIENT CHARACTERISTICS:~* WHO performance status 0-1~* Life expectancy ≥ 3 months~* Hemoglobin ≥ 10 g/dL~* Platelet count ≥ 100 x 10\^9/L~* Neutrophil count ≥ 2.0 x 10\^9/L~* Lymphocyte count ≥ 1.0 x 10\^9/L~* Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)~* ALT/AST ≤ 5 times ULN~* Alkaline phosphatase ≤ 5 times ULN~* Calculated creatinine clearance OR isotope clearance measurement ≥ 50 mL/min~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception 4 weeks prior to, during, and for 6 months after completion of study therapy (male patients must use barrier-method contraception)~* LVEF ≥ 50% on MUGA scan (for patients receiving cyclophosphamide)~* ECG and exercise ECG (or stress ECHO) normal (may be abnormal but not clinically significant)~* Urine dipstick normal (may be abnormal but not clinically significant)~* No medical high risk due to nonmalignant systemic disease including active uncontrolled infection~* No known serologically positive hepatitis B, hepatitis C, HIV, or HTLV~* No history of autoimmune disease~* No inflammatory bowel disease~* No concurrent congestive heart failure or prior history of NYHA class III-IV cardiac disease~* No concurrent malignancies originating from other primary sites, except for adequately treated cone-biopsied carcinoma in situ of the cervix uteri or basal cell or squamous cell carcinoma of the skin~* No other condition that, in the investigator's opinion, would make the patient an unsuitable candidate for the clinical trial~PRIOR CONCURRENT THERAPY:~* At least 30 days since prior and no concurrent participation in another clinical trial~* At least 4 weeks since prior and no concurrent radiotherapy (except for palliative reasons \[i.e., control of bone pain\])~* At least 4 weeks since prior and no concurrent endocrine therapy, immunotherapy, or chemotherapy (6 weeks for nitrosoureas and mitomycin C)~* No toxic manifestations of previous treatment, except for alopecia or certain grade 1 toxicities that, in the opinion of the investigator and CRUK (Cancer Research UK), would exclude the patient (e.g., grade 1 neuropathy or grade 1 fatigue)~* No prior major thoracic and/or abdominal surgery from which the patient has not yet recovered~* No prior bone marrow transplant or extensive radiotherapy to \> 25% of bone marrow~* No concurrent systemic steroids or other immunosuppressive therapy~* No other concurrent anticancer therapy or investigational drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy